Based on discoveries that various amino acid substitutions led to an increased anti-proliferative activity of GnRH-III derivatives on GnRH-R positive prostate cancer cell lines [36], similar, as well as related modifications have been applied and investigated for oxime bond containing GnRH-III-Dau conjugates, whereby an N-terminal sequence modification led to an improved anti-tumor activity [37]. This evidence concerns the gene GNRH1 and Familial prostate cancer.